Lupin Launches Risperidone Long-Acting Injectable in the U.S.

Mumbai, November 14: Lupin Limited has announced that it has launched its long-acting injectable Risperidone in the United States. It has also secured an exclusivity of 180 days. The injection is the first product that Lupin has developed using its PrecisionSphere technology.

PrecisionSphere is a long-acting injectable platform built by Lupin’s subsidiary Nanomi B.V. The company has launched the product in 25 mg, 37.5 mg, and 50 mg single-dose vials. The injectable is used to treat schizophrenia in adults. It is also used in monotherapy or adjunctive therapy with lithium or valproate for maintenance treatment of bipolar I disorder in adults.

Shares Rise by 0.52% At ₹2,063.60

As of 9:40 AM, Lupin’s share price was up by 0.52%, or 10.70 points, and was trading at ₹2,063.60. The traded volume stood at 41.69 thousand shares, with the company’s market at ₹93,769 crore.

Investor Takeaway n

The launch of its long-acting injectable Risperidone in the United States by Lupin is a welcome sign for the company, as it will add to its product portfolio. The new product is likely to contribute to its revenue and potentially add to its profits in the coming quarters. The launch has boosted investor sentiments, leading to a rise in Lupin’s share price.

REF: https://nsearchives.nseindia.com/corporate/Lupin2_14112025071540_SE_LetterwithPressRelease_14112025.pdf

Disclaimer: At HDFC SKY, we take utmost care and due diligence in curating and presenting news and market-related content. However, inadvertent errors or omissions may occasionally occur.

If you have any concerns, questions, or wish to point out any discrepancies in our content, please feel free to write to us at content@hdfcsec.com.

Please note that the information shared is intended solely for informational purposes and does not make any investment recommendations